Tue. 13 Feb 2024, 7:11am ET
Benzinga
News, Guidance
Incyte's guidance includes revenues and expenses related to the recently announced acquisition of exclusive global rights to tafasitamab and excludes any potential impact related to the accounting treatment of the $25 million purchase price paid.